Skip to content

Safety Assessment of pH-D New Instant Rinse for One Time Use

Safety Assessment of pH-D New Instant Rinse for One Time Use

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07802483
Enrollment
90
Registered
2026-09-03
Start date
2026-09-01
Completion date
2026-10-31
Last updated
2026-09-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vaginal Odor

Keywords

vaginal odor, foam wash, vaginal rinse

Brief summary

Demonstrate the safety characteristics of new formulations of pH-D foam wash and instant rinse

Interventions

OTHERLactic Acid instant odor rinse

Lactic Acid instant odor rinse

OTHERBoric Acid instant odor rinse

Boric acid one time use instant odor rinse

OTHERPlacebo

base solution rinse

Sponsors

pH-D Feminine Health LLC
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
OTHER
Masking
DOUBLE (Subject, Caregiver)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Non-pregnant females, 18 years and older 2. Complaint of abnormal vaginal odor with or without complaints of discharge 3. Odor rated ≥4 on a 0-10 numerical rating scale (NRS) (0 = NO odor, 10 = strong unpleasant odor) 4. Willing/able to comply with study requirements 5. Has provided informed consent 6. Subject has regular cycle length of 24-35 days

Exclusion criteria

1. Patients genital lesions or ulcers consistent with human papillomavirus (HPV), Herpes simplex, syphilis, chancroid, etc.). Patients with a history of genital herpes or condylomata who have been asymptomatic for at least 3 months may be considered for eligibility. 2. Patients who will undergo evaluation or treatment during the study for abnormal cytology and/or findings from high risk HPV testing and/or Pap test finding. 3. Subjects with lower genital tract infections (e.g. symptomatic VVC, trichomoniasis, HSV) diagnosed in the past 30 days 4. Subjects with other Vaginal or Vulvar condition that would interfere with clinical interpretation of data (e.g. vaginal or vulvar dysplasia, lichen sclerosis) 5. Subject has received antibiotic or antifungal treatment in the past 14 days 6. Subject is currently menstruating or is expected to menstruate in the next 7 days. Patients will be enrolled but start suppositories after menses has concluded 7. Investigator considers a medical or other identifiable reason for subject's vaginal odor \-

Design outcomes

Primary

MeasureTime frame
Written questionnaire to assess outcomes of the single use vaginal odor rinse72 hours

Contacts

CONTACTMark Martens, M.D.
markgmartens@gmail.com918-607-4909
CONTACTWilliam Faulkner, MBA
bfaulkner@talmont-holdings.com6513436370

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 4, 2026